Variable | Overall survival | Relapse-free survival | ||
---|---|---|---|---|
HR (95% Cl) | p | HR (95% Cl) | p | |
CA125 | 1 (1–1) | 0.14 | 1 (1–1) | 0.31 |
Stage | 0.55 | 0.8 | ||
Stage I | 1 | 1 | ||
Stage II | 0.61 (0.12–3.14] | 0.52 | 1.14 (0.4–3.19) | 0.808 |
Stage III | 2.99 (1.21–7.43] | 0.018 | 2.64 (1.33–5.26) | 0.006 |
Stage IV | 5.35 (1.63–17.57) | 0.006 | 4.84 (1.79–13.09) | 0.002 |
Debulking | 0.22 | 0.08 | ||
Debulking R0 | 1 | 1 | ||
Debulking R1 | 1.67 (0.73–3.8) | 0.224 | 1.84 (0.92–3.67) | 0.084 |
Debulking R2 | 2.17 (1.36–3.47) | 0.001 | 2.76 (1.85–4.13) | < 0.0001 |
Age | 1 (0.98–1) | 0.73 | 1 (0.99–1) | 0.48 |
CALR | 0.96 (0.94–0.98) | < 0.0001 | 0.97 (0.95–0.98) | < 0.0001 |
DC-LAMP summary | 0.86 (0.76–0.96) | 0.0097 | 0.98 (0.94–1) | 0.19 |
CD8 summary | 1 (1–1) | 0.011 | 1 (1–1) | 0.057 |
CD20 | 0.2 (0.039–0.97) | 0.046 | 0.5 (0.23–1.1) | 0.087 |
NKp46 | 1 (0.82–1.2) | 0.98 | 0.91 (0.73–1.1) | 0.42 |